Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
23
7
2020
medline:
29
9
2021
entrez:
23
7
2020
Statut:
ppublish
Résumé
Multiple studies have shown that pharmacologic treatments for attention-deficit hyperactivity disorder (ADHD), especially stimulants, are generally effective. There is yet a paucity of empirical data, however, for some common clinical conditions overlooked in the ADHD treatment guidelines. Some examples include: in cases of first line treatment failure, it is unclear whether switching from one type of stimulant to another is beneficial. In cases of comorbid ADHD and severe aggressive/disruptive behavior in children, it is unclear whether the best first-line treatment is stimulants or atypical antipsychotics like risperidone. In cases of ADHD with comorbid anxiety disorders, there is no clear evidence regarding optimal treatment. The objectives of this article are to review these issues and propose possible answers for such clinical dilemmas.
Identifiants
pubmed: 32694317
doi: 10.1097/YIC.0000000000000323
pii: 00004850-202011000-00002
doi:
Substances chimiques
Antidepressive Agents
0
Antipsychotic Agents
0
Central Nervous System Stimulants
0
Risperidone
L6UH7ZF8HC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
300-304Références
Abikoff H, McGough J, Vitiello B, McCracken J, Davies M, Walkup J, et al.; RUPP ADHD/Anxiety Study Group. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am ACAD Child Adolesc Psychiatry. 2005; 44:418–427
Adler LA, Barkley RA, Newcorn JH, Spencer TJ, Weiss MD. Managing ADHD in children, adolescents, and adults with comorbid anxiety in primary care. Prim Care Companion J Clin Psychiat. 2007; 9:129–138
Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004; 14:243–254
APA. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011; 128:1007–1022
Arabgol F, Panaghi L, Nikzad V. Risperidone versus methylphenidate in treatment of preschool children with attention-deficit hyperactivity disorder. Iran J Pediatr. 2015; 25:e265
Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007; 46:558–565
Arnold LE. Methylphenidate vs. amphetamine: comparative review. J Atten Disord. 2000; 3:200–211
Bolea-Alamañac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, et al.; British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014; 28:179–203
Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008; 299:901–913
CADDRA. Canadian ADHD Resource Alliance (CADDRA): Canadian ADHD Practice Guidelines. 20184th ed, Toronto ON: CADDRA
Caye A, Swanson JM, Coghill D, Rohde LA. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry. 2019; 24:390–408
Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH Jr. Psychopharmacology and aggression. I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002; 41:253–261
Correia Filho AG, Bodanese R, Silva TL, Alvares JP, Aman M, Rohde LA. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am ACAD Child Adolesc Psychiatry. 2005; 44:748–755
Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011; 17:97–107
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009; 302:1765–1773
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018; 5:727–738
Coughlin CG, Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Bloch MH. Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2015; 25:611–617
Dittmann RW, Cardo E, Nagy P, Anderson CS, Adeyi B, Caballero B, et al. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. CNS Drugs. 2014; 28:1059–1069
Edelsohn GA, Karpov I, Parthasarathy M, Hutchison SL, Castelnovo K, Ghuman J, Schuster JM. Trends in antipsychotic prescribing in medicaid-eligible youth. J Am Acad Child Adolesc Psychiatry. 2017; 56:59–66
Epstein RA, Fonnesbeck C, Potter S, Rizzone KH, McPheeters M. Psychosocial interventions for child disruptive behaviors: a meta-analysis. Pediatrics. 2015; 136:947–960
Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008; 47:994–1009
Farmer CA, Brown NV, Gadow KD, Arnold LE, Kolko DG, Findling RL, et al. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2015; 25:213–224
Frank E, Ozon C, Nair V, Othee K. Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis. J Clin Psychiatry. 2015; 76:e1459–e1468
Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol. 2018; 28:1059–1088
Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46:1119–1127
Gibson AP, Bettinger TL, Patel NC, Crismon ML. Atomoxetine versus stimulants for treatment of attention deficiti/hyperactivity disorder. Ann Pharmacother. 2006; 40:1134–1142
Gillberg C, Gillberg IC, Rasmussen P, Kadesjö B, Söderström H, Råstam M, et al. Co-existing disorders in ADHD – implications for diagnosis and intervention. Eur Child Adolesc Psychiatry. 2004; 92:80–92
Gorman DA, Gardner DM, Murphy AL, Feldman M, Bélanger SA, Steele MM, et al. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder. Can J Psychiatry. 2015; 60:62–76
Günther T, Herpertz-Dahlmann B, Jolles J, Konrad K. The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder. J Child Adolesc Psychopharmacol. 2006; 16:725–735
Jahangard L, Akbarian S, Haghighi M, Ahmadpanah M, Keshavarzi A, Bajoghli H, et al. Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed – results from a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res. 2017; 251:182–191
Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004; 14:11–28
Liu Q, Zhang H, Fang Q, Qin L. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials. J Clin Exp Neuropsychol. 2017; 39:854–865
Masi G, Manfredi A, Nieri G, Muratori P, Pfanner C, Milone A. A naturalistic comparison of methylphenidate and risperidone monotherapy in drug-naive youth with attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder and aggression. J Clin Psychopharmacol. 2017; 37:590–594
Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D; Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J psychiatry. 2008; 165:721–730
NICE. Attention deficit h hyper yperactivity activity disorder: diagnosis and management. NICE Guidel. 2018
Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxf.). 2007; 21:10–41
Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry. 2015; 72:867–874
Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, et al.; Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. The Texas children’s medication algorithm project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am ACAD Child Adolesc Psychiatry. 2006; 45:642–657
Pliszka SR. The use of psychostimulants in the pediatric patient. Pediatr Clin North Am. 1998; 45:1085–1098
Pringsheim T, Hirsch L, Gardner D, Gorman DA. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers. Can J Psychiatry. 2015; 60:52–61
Riera M, Castells X, Tobias A, Cunill R, Blanco L, Capellà D. Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients. Psychopharmacology (Berl). 2017; 234:2657–2671
Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine. Curr Med Res Opin. 2014; 30:1673–1685
Seixas M, Weiss M, Müller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol. 2012; 26:753–765
Strawn JR, Dobson ET, Giles LL. Primary pediatric care psychopharmacology: focus on medications for ADHD, depression, and anxiety. Curr Probl Pediatr Adolesc Health Care. 2017; 47:3–14
Sultan RS, Wang S, Crystal S, Olfson M. Antipsychotic treatment among youths with attention-deficit/hyperactivity disorder. JAMA Netw Open. 2019; 2:e197850
Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am ACAD Child Adolesc psychiatry. 2007; 46:1015–1027
Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am ACAD Child Adolesc Psychiatry. 2012; 51:74–85.e2